Quick Answer
NewAmsterdam Pharma Co N.V. reported Total Revenue of $22.50 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $22.50M -50.6% |
$45.56M +223.4% |
$14.09M -86.3% |
$102.69M | — | — |
| Revenue (ASC 606) | $22.50M -50.6% |
$45.56M +223.4% |
$14.09M -86.3% |
$102.69M | — | — |
| Net Income | -$203.82M +15.6% |
-$241.60M -36.5% |
-$176.94M -681.7% |
-$22.63M +45.8% |
-$41.78M | — |
| Diluted EPS | -$1.72 +32.8% |
-$2.56 -19.1% |
-$2.15 -80.7% |
-$1.19 +68.8% |
-$3.81 | — |
| Total Assets | $769.28M -11.0% |
$864.62M +149.1% |
$347.10M -27.5% |
$478.50M +700.4% |
$59.78M | — |
| Cash and Equivalents | $490.00M -36.5% |
$771.74M +126.7% |
$340.45M | — | — | — |
| Stockholders Equity | $683.43M -9.8% |
$757.50M +162.7% |
$288.39M -32.9% |
$430.07M +477.9% |
-$113.82M -55.8% |
-$73.03M |
| R&D Expense | $141.83M -6.3% |
$151.41M -5.0% |
$159.42M +83.8% |
$86.74M +199.4% |
$28.97M +616.3% |
$4.04M |
| Operating Income | -$225.68M -28.0% |
-$176.29M +3.6% |
-$182.97M -5043.9% |
-$3.56M +89.8% |
-$34.98M | — |
| Shares Outstanding | 114.40M +5.9% |
108.06M +31.0% |
82.47M +127.5% |
36.26M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $348.0K | -98.8% | -98.2% |
| Revenue (ASC 606) | September 30, 2025 | $348.0K | -98.8% | -98.2% |
| Net Income | September 30, 2025 | -$72.00M | -332.5% | -314.7% |
| Diluted EPS | September 30, 2025 | -$0.61 | -238.9% | -306.7% |
| Total Assets | September 30, 2025 | $786.43M | +79.1% | -3.5% |
| Cash and Equivalents | September 30, 2025 | $538.41M | +27.4% | -4.5% |
| Stockholders Equity | September 30, 2025 | $728.07M | +92.2% | -6.5% |
| R&D Expense | September 30, 2025 | $30.97M | -13.3% | +12.6% |
| Operating Income | September 30, 2025 | -$55.14M | -120.5% | -54.7% |
| Shares Outstanding | September 30, 2025 | 113.17M | +22.8% | +0.6% |
- NewAmsterdam Pharma Co N.V. reported Total Revenue of $22.50 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -50.6% in Total Revenue compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Revenue (ASC 606) of $22.50 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -50.6% in Revenue (ASC 606) compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Net Income of -$203.82 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed an increase of +15.6% in Net Income compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Diluted EPS of $1.72 per share (loss) for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed an increase of +32.8% in Diluted EPS compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Total Assets of $769.28 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -11.0% in Total Assets compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Cash and Equivalents of $490.00 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -36.5% in Cash and Equivalents compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Stockholders Equity of $683.43 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -9.8% in Stockholders Equity compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported R&D Expense of $141.83 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -6.3% in R&D Expense compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Operating Income of -$225.68 million for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed a decrease of -28.0% in Operating Income compared to the prior fiscal year.
- NewAmsterdam Pharma Co N.V. reported Shares Outstanding of 114.40 million shares for fiscal year 2025.
- NewAmsterdam Pharma Co N.V. showed an increase of +5.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: